Chimeric antigen receptor constructs and uses thereof

By combining chimeric antigen receptor T-cell therapy with GAM regulation, utilizing EGFRvIII and CD19 as tumor-targeting antigens, and releasing high-affinity SGRP to enhance CD47 blockade, the challenges of GBM treatment have been solved, achieving effective clearance of GBM and prolonging survival time.

CN122161612APending Publication Date: 2026-06-05OFFICE OF THE VICE-RECTOR FOR RESEARCH AT THE UNIVERSITY OF BASEL
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
OFFICE OF THE VICE-RECTOR FOR RESEARCH AT THE UNIVERSITY OF BASEL
Filing Date
2024-08-29
Publication Date
2026-06-05

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to a polynucleotide molecule comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) or fragment thereof, said chimeric antigen receptor (CAR) or fragment thereof i) comprising an extracellular domain comprising an antigen binding region that binds to epidermal growth factor receptor variant III (EGFRvIII); or ii) comprising an extracellular domain comprising an antigen binding region that binds to CD19; wherein the nucleotide sequence encoding the CAR is operably linked to a promoter, and wherein the polynucleotide molecule further comprises a nucleotide sequence encoding a heterologous signal peptide fused to a signal regulatory protein gamma (SIRPy)-related protein (SGRP). The present invention further relates to a chimeric antigen receptor (CAR)-T cell expressing the polynucleotide molecule, as well as a method of treating cancer using said polynucleotide molecule and / or a chimeric antigen receptor (CAR)-T cell expressing said polynucleotide molecule.
Need to check novelty before this filing date? Find Prior Art